文献速递肝病消化道肿瘤与早癌

直接抗病毒药物治疗后肝细胞癌复发:个体患者数据荟萃分析

Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis.
PubMed 文献 · Gut · 2021-03-19

该个体患者数据荟萃分析纳入21项研究共977例HCV相关肝硬化合并HCC、经手术/局部治疗后达完全影像学缓解并接受DAA治疗的患者,复发率为20/100人年,死亡风险为5.7/100人年;倾向评分匹配后DAA暴露组与未暴露组的HCC复发风险无显著差异(RR=0.64,95%CI 0.37-1.1,p=0.1)。

要点

  • DAA治疗后HCC复发率为20/100人年,死亡风险为5.7/100人年。
  • AFP对数、既往HCC复发史、体能状态及肿瘤负荷为复发预测因素。
  • 倾向评分匹配后DAA暴露与未暴露组复发风险无显著差异。

核心结论

  • DAA暴露对HCC复发风险的影响尚不确定,对HCC患者经DAA根除HCV后应积极进行临床和影像学随访。

研究设计与样本

  • 个体患者数据荟萃分析,汇总21项研究共977例HCV相关肝硬化合并HCC、经手术/局部治疗后达完全影像学缓解并接受DAA治疗的患者。
  • 倾向评分匹配的ITA.LI.CA.队列328例未暴露于DAA的患者作为对照。

主要发现

  • DAA治疗患者复发率为20/100人年(95%CI 13.9-29.8,I2=74.6%),死亡风险为5.7/100人年(95%CI 2.5-15.3,I2=54.3%)。
  • 复发预测因素包括AFP对数(每1 log ng/mL,RR=1.11,95%CI 1.03-1.19,p=0.01)、DAA开始前HCC复发史(RR=1.11,95%CI 1.07-1.16,p<0.001)、体能状态(2 vs 0,RR=4.35,95%CI 1.54-11.11;2 vs 1,RR=3.7,95%CI 1.3-11.11;p=0.01)及HCC治疗前肿瘤负荷(多灶 vs 单结节,RR=1.75,95%CI 1.25-2.43,p<0.001)。
  • 倾向评分匹配患者中,DAA暴露组与未暴露组的复发相对风险无显著差异(RR=0.64,95%CI 0.37-1.1,p=0.1)。

临床怎么用

  • 对接受DAA治疗的HCC完全缓解患者,应加强临床和影像学随访以监测复发。
  • 关注AFP水平、既往HCC复发史、体能状态及肿瘤负荷等复发预测因素。

局限性

  • DAA暴露对HCC复发风险的影响尚不确定,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The benefit of direct-acting antivirals (DAAs) against HCV following successful treatment of hepatocellular carcinoma (HCC) remains controversial. This meta-analysis of individual patient data assessed HCC recurrence risk following DAA administration. DESIGN: We pooled the data of 977 consecutive patients from 21 studies of HCV-related cirrhosis and HCC, who achieved complete radiological response after surgical/locoregional treatments and received DAAs (DAA group). Recurrence or death risk was expressed as HCC recurrence or death per 100 person-years (100PY). Propensity score-matched patients from the ITA.LI.CA. cohort (n=328) served as DAA-unexposed controls (no-DAA group). Risk factors for HCC recurrence were identified using random-effects Poisson. RESULTS: Recurrence rate and death risk per 100PY in DAA-treated patients were 20 (95% CI 13.9 to 29.8, I2=74.6%) and 5.7 (2.5 to 15.3, I2=54.3), respectively. Predictive factors for recurrence were alpha-fetoprotein logarithm (relative risk (RR)=1.11, 95% CI 1.03 to 1.19; p=0.01, per 1 log of ng/mL), HCC recurrence history pre-DAA initiation (RR=1.11, 95% CI 1.07 to 1.16; p<0.001), performance status (2 vs 0, RR=4.35, 95% CI 1.54 to 11.11; 2 vs 1, RR=3.7, 95% CI 1.3 to 11.11; p=0.01) and tumour burden pre-HCC treatment (multifocal vs solitary nodule, RR=1.75, 95% CI 1.25 to 2.43; p<0.001). No significant difference was observed in RR between the DAA-exposed and DAA-unexposed groups in propensity score-matched patients (RR=0.64, 95% CI 0.37 to 1.1; p=0.1). CONCLUSION: Effects of DAA exposure on HCC recurrence risk remain inconclusive. Active clinical and radiological follow-up of patients with HCC after HCV eradication with DAA is justified.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Sapena V, Enea M, Torres F, et al. Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. Gut. 2021. PMID: 33741640. doi:10.1136/gutjnl-2020-323663

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。